Upside, Downside Movers in the Morning
Upside
– $CNTB +83% (Phase 2 COPD trial met its primary endpoint, reducing treatment failures by 81% and new moderate-to-severe exacerbations by 85%)
– $NAUT +16% (no clear fresh catalyst identified; unusually large, liquid premarket move)
– $CAPR +14% (new deramiocel analyses showed slower upper-limb decline in the HOPE-3 open-label extension and versus natural history)
– $BIYA +13% (first-half results showed new continuing-operations revenue and a narrower net loss)
– $SGMT +9.0% (rises ahead of today’s KOL event on 52-week Phase 3 extension data and the planned US AURORA Phase 3 trial)
– $KALA +5.3% (signs a non-binding agreement to acquire a nationwide telehealth platform for approximately $15M)
– $HPE +4.2% (no clear fresh catalyst identified; unusually large premarket move in a major liquid stock)
Downside
– $PYXS -16% (prices a public offering of up to $282.6M, adding substantial dilution and stock supply)
– $SDEV -15% (pulls back after the prior session’s outsized speculative surge)
– $CNXC -8.7% (quarterly profitability topped guidance, but Q4 sales and profit guidance came in light and the FY revenue outlook missed expectations)